NEW YORK, July 19, 2026 – AtaiBeckley (NASDAQ:ATAI) shares closed Friday at $7.22, marking a 39.7% weekly gain, as the market priced the merger contingent value right (CVR) at approximately 19% of its face value. The stock's rise outpaced the broader market, with the Nasdaq Composite falling 2.9% over the same period.
The CVR, which is part of Eli Lilly's (NYSE:LLY) acquisition agreement, has a maximum payout of $2.50 per share, tied to three milestones. Based on Friday's closing price, the CVR is initially valued at $0.47, or 18.8% of the potential maximum. This valuation excludes time value, deal closing risks, and the possibility of a competing offer.
The acquisition by Eli Lilly offers AtaiBeckley shareholders a cash payment of $6.75 per share at closing, representing a 25.9% premium to the $5.36 baseline price on July 15. The total potential value, including the maximum CVR payout, reaches $9.25 per share, which is 28.1% higher than Friday's closing price.
Eli Lilly anticipates completing the acquisition in the third quarter of 2026, subject to approval from a majority of shareholders and regulatory clearance. There is no financing condition attached to the deal. A regulatory filing on Friday revealed that a 15.4% shareholder group, led by Christian Angermayer and associated entities, has committed to backing the takeover, though this stake alone does not provide majority control.
The CVR payments are contingent on specific milestones. The first $1 payment depends on VLS-01 advancing to Phase 3 trials within four years. The subsequent payments are linked to U.S. regulatory approvals and potential drug rescheduling. The CVRs are expected to be unlisted and mostly non-transferable, with Lilly required to make commercially reasonable efforts but not obligated to accelerate payments.
Trading activity was robust, with 207.9 million shares changing hands on Thursday and Friday, representing 56.5% of shares outstanding. Shares can be traded multiple times. AtaiBeckley closed at a 52-week high on Friday, reflecting strong investor interest.
Analysts have weighed in on the deal's potential. Barclays (NYSE:BCS) analyst Emily Field noted that the acquisition offers upside potential in large markets like depression. Jefferies Financial Group (NYSE:JEF) analyst Andrew Tsai highlighted that successful sales of BPL-003, the company's intranasal treatment for treatment-resistant depression, could exceed $1 billion, with a possible upside of $2 billion. BPL-003 has received Breakthrough Therapy designation from the FDA, and Phase 3 trials are underway, with preliminary data expected in early 2029.
The company plans to submit a shareholder proxy, though a vote date has not yet been scheduled. Investors are advised to monitor regulatory filings and await approval. Nasdaq's regular trading session resumes Monday at 9:30 a.m. EDT.
Risks include potential delays or failure to close the deal, as well as the unlisted nature of the CVRs. While Lilly is committed to making commercially reasonable efforts, it is not obligated to increase or accelerate payments.
